Thursday, October 31, 2013

Seeking Alpha: Xenoport Looks To '829 To Restore Its Lost Glory

Five years ago, XenoPort (XNPT) was a $40 stock, but while the biotech sector has enjoyed a strong run these shares have gone the other way on disappointments over the restless leg drug Horizant and the clinical failures of arbaclofen placarbil. Although I don't see a credible path back to $40 anytime soon, the company's monomethyl fumarate (MMF) prodrug XPS23829 ('829) does give the company at least a fighting chance of grabbing some of the billions of dollars in revenue expected for Biogen Idec's (BIIB) latest blockbuster Tecfidera. While the prospect of capturing some of Tecfidera's potential sales through competitive pricing or clinical differentiation is intriguing, investors shouldn't kid themselves about the risks and uncertainties still in play here.

Read the full article here:
Xenoport Looks To '829 To Restore Its Lost Glory

No comments: